Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076517 | 0.83 | CNR2 (0.49) | CNR2SMN1; SMN2GAALMNAALDH1A1 | |
| SCHEMBL3082523 | 0.80 | CNR2 (0.53) | CNR2SMN1; SMN2GAALMNAALDH1A1 | |
| SCHEMBL28848742 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2GAALMNAALDH1A1MAPK1 | |
| SCHEMBL3082994 | 0.80 | CNR2 (0.54) | CNR2HTT | |
| SCHEMBL8109858 | 0.73 | CTSB (0.70) | — | |
| SCHEMBL3074624 | 0.73 | DPP4 (0.61) | CNR2SMN1; SMN2LMNAALDH1A1MAPK1 | |
| SCHEMBL3085718 | 0.72 | SMN1; SMN2 (0.57) | SMN1; SMN2GAALMNAALDH1A1MAPK1 | |
| SCHEMBL3075247 | 0.72 | MAPT (0.77) | CNR2SMN1; SMN2LMNAALDH1A1MAPK1 | |
| SCHEMBL3086401 | 0.71 | MAPT (0.66) | CNR2GAALMNAALDH1A1 | |
| SCHEMBL3084495 | 0.71 | CNR2 (1.00) | CNR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | claimed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | claimed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | CNR2 2/4885SMN1; SMN2 4612/4885GAA 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.